Henan Lingrui Pharmaceutical Co Ltd
SSE:600285

Watchlist Manager
Henan Lingrui Pharmaceutical Co Ltd Logo
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Watchlist
Price: 22.48 CNY 1.4% Market Closed
Market Cap: 12.7B CNY
Have any thoughts about
Henan Lingrui Pharmaceutical Co Ltd?
Write Note

Relative Value

The Relative Value of one Henan Lingrui Pharmaceutical Co Ltd stock under the Base Case scenario is 26.09 CNY. Compared to the current market price of 22.48 CNY, Henan Lingrui Pharmaceutical Co Ltd is Undervalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
26.09 CNY
Undervaluation 14%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
9
vs Industry
32
Median 3Y
2.8
Median 5Y
2.6
Industry
2.5
Forward
3.3
vs History
28
vs Industry
22
Median 3Y
18.1
Median 5Y
17.4
Industry
21.8
Forward
17.9
vs History
3
vs Industry
24
Median 3Y
11.3
Median 5Y
10.6
Industry
16.1
vs History
15
vs Industry
23
Median 3Y
11.6
Median 5Y
12.5
Industry
23.8
vs History
7
vs Industry
16
Median 3Y
3.5
Median 5Y
3
Industry
2.1
vs History
7
vs Industry
33
Median 3Y
2.4
Median 5Y
2.2
Industry
2.7
Forward
3.1
vs History
7
vs Industry
42
Median 3Y
3.3
Median 5Y
3.1
Industry
5.2
vs History
33
vs Industry
20
Median 3Y
16
Median 5Y
14.6
Industry
13.5
Forward
14.1
vs History
33
vs Industry
23
Median 3Y
16
Median 5Y
14.6
Industry
16.8
Forward
15.2
vs History
3
vs Industry
27
Median 3Y
9.4
Median 5Y
9.4
Industry
15.2
vs History
3
vs Industry
23
Median 3Y
10
Median 5Y
10.2
Industry
19.3
vs History
12
vs Industry
22
Median 3Y
2.7
Median 5Y
2.2
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Henan Lingrui Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
12.7B CNY 3.6 18.7 16.5 16.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
749.1B USD 18.5 89.9 48.1 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
348B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
150.1B USD 2.5 35.4 10.5 15.9
P/E Multiple
Earnings Growth P/E to Growth
CN
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Average P/E: 30.8
18.7
71%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.9
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.4
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Average EV/EBITDA: 415.2
16.5
84%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Average EV/EBIT: 1 811.7
16.5
74%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

See Also

Discover More
Back to Top